Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma [Phase 2]
This is a Phase 2 trial evaluating a combination of mosunetuzumab and polatuzumab vedotin with split-dose CHP chemotherapy in elderly patien…
-
CLINICAL_TRIALS trial_result · 2026-02-04Clinical Trial Update: Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) [Phase 2]
Phase 2 clinical trial update for Purinostat Mesylate in relapsed or refractory diffuse large B-cell lymphoma, with the study currently acti…
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma [EARLY_Phase 1]
Phase I master protocol trial evaluating a novel combination therapy for patients with relapsed or refractory aggressive B-cell lymphomas.
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma [Phase 2]
Phase 2 study evaluating axicabtagene ciloleucel given with steroids in relapsed or refractory diffuse large B-cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma [Phase 1]
An early-phase study evaluating the combination of parsaclisib with standard therapy in newly diagnosed, high-risk diffuse large B-cell lymp…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell
An observational study of people living with HIV treated with CD19-directed CAR T-cell therapy has completed.
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma
This is a clinical trial update describing a study to evaluate the effectiveness and safety of Polivy (polatuzumab vedotin) in real-world Ch…
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma [Phase 2]
A Phase 2 clinical trial update describes testing additional drug treatments after CAR T-cell therapy in patients with relapsed or refractor…
-
CLINICAL_TRIALS withdrawal · 2026-01-30Clinical Trial Update: Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating Rituximab, Venetoclax, and Bortezomib for relapsed or refractory diffuse large B-cell lymphoma has been withdrawn…
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma [Phase 1, Phase 2]
A phase 1/2 clinical trial of TQB2825 injection combined with immunochemotherapy for Diffuse Large B Cell Lymphoma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas [Phase 2]
Phase 2 study evaluating acalabrutinib plus lisocabtagene maraleucel (Liso-Cel) in refractory/relapsed aggressive B-cell lymphomas, includin…
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: Split-Dose R-CHOP for Older Adults With DLBCL [Phase 2]
Phase 2 trial update reporting results for split-dose R-CHOP in older adults with Diffuse Large B-Cell Lymphoma; results were posted on 2026…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy [Phase 2]
A Phase 2 trial is evaluating whether vaccination with Prevnar 13 before and after CAR-T therapy can enhance cellular and humoral immunity i…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating zanubrutinib-based combination regimens for newly diagnosed diffuse large B-cell lymphoma; currently recru…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy [Phase 2]
A Phase 2 clinical trial investigates golcadomide in combination with rituximab as bridging therapy for relapsed or refractory aggressive B-…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma [Phase 1]
A Phase 1 safety and efficacy study of anti-PD1 armored CD19 CAR-T cells in adults with relapsed or refractory diffuse large B-cell lymphoma…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Clinical trial registry update for the RUBIN platform extension focusing on hematologic malignancies. It is currently recruiting for conditi…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy [Phase 3]
Phase 3 clinical trial evaluating a digital health intervention for self-management and telemonitoring in CAR-T therapy is currently recruit…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Quality Of Life and Drug Use in Patients With CAR-T Cells
Clinical trial update focused on quality of life and drug use in patients treated with CAR-T cells for diffuse large B-cell lymphoma. The st…
-
EMA approval · 2026-01-27EMA Authorised: Minjuvi (tafasitamab) — Incyte Biosciences Distribution B.V.
EMA authorised Minjuvi (tafasitamab) for diffuse large B-cell lymphoma with conditional approval and orphan designation.
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies [Phase 1]
A Phase 1 clinical trial evaluates PRT2527 as a standalone therapy and in combination with zanubrutinib or venetoclax for relapsed/refractor…
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers [Phase 1]
A Phase 1 safety study of PF-08046045/SGN-35T sponsored by Seagen has been terminated in adults with advanced lymphomas and Hodgkin disease.
-
CLINICAL_TRIALS trial_result · 2026-01-23Clinical Trial Update: MT2017-45: CAR-T Cell Therapy for Heme Malignancies [Phase 2]
Phase 2 trial MT2017-45 CAR-T cell therapy for hematologic malignancies has an active-not-recruiting status with results posted as of 2026-0…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL [NA]
This clinical trial update describes a study evaluating ctDNA-guided therapy optimization for newly diagnosed diffuse large B-cell lymphoma,…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ [Phase 2]
This clinical trial update reports a Phase 2 study evaluating zanubrutinib in patients with diffuse large B-cell lymphoma who have MYD88 or …